GSK At J.P.M. Updates On Breo Launch, Rare Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
Following several setbacks in 2014, GSK’s rare disease business is “a work in progress” and the company will look for partnerships to maximize potential of its remaining assets in that category; meanwhile the closely watched Breo launch is meeting expectations despite bumps created when large pharmacy benefits managers, in highly publicized moves, took the drug off their formularies.
You may also be interested in...
FDA Approves GSK’s Anoro Ellipta, The First LABA/LAMA Combination
FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.
GSK’s Big Push To Maintain Its Respiratory Reign
GlaxoSmithKline is counting on new products like Breo Ellipta and Anoro Ellipta to extend its legacy in respiratory disease beyond Advair Diskus, which could face generic competition within the next five years. But GSK may need to wage a battle on the reimbursement front before it can claim commercial success – a challenge highlighted by Express Scripts’ unexpected decision to put Advair and Breo on its not covered list for 2014.
Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?